Nothing in biotech is a sure thing; however, from a regulatory standpoint, there is nothing equivocal in the SAKURA-1/2/3 datasets, and I'm confident that RVNC has the CMC portion of the BLA under control.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”